{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Malignant+Gliomas",
    "query": {
      "condition": "Recurrent Malignant Gliomas"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 440,
    "total_pages": 44,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Malignant+Gliomas&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T14:14:15.745Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02197169",
      "title": "DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma or Gliosarcoma"
      ],
      "interventions": [
        {
          "name": "Single intratumoral injection of DNX-2401",
          "type": "DRUG"
        },
        {
          "name": "Interferon-gamma",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "DNAtrix, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2014-09-11",
      "completion_date": "2018-03-15",
      "has_results": false,
      "last_update_posted_date": "2018-07-16",
      "last_synced_at": "2026-07-22T14:14:15.745Z",
      "location_count": 4,
      "location_summary": "Tampa, Florida • Columbus, Ohio • Dallas, Texas + 1 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02197169"
    },
    {
      "nct_id": "NCT03973918",
      "title": "Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "High Grade Glioma",
        "BRAF V600E",
        "BRAF V600K",
        "Anaplastic Astrocytoma",
        "Anaplastic Pleomorphic Xanthoastrocytoma",
        "Gliosarcoma",
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Encorafenib",
          "type": "DRUG"
        },
        {
          "name": "Binimetinib",
          "type": "DRUG"
        },
        {
          "name": "Research Bloods",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tumor Tissue",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2019-07-29",
      "completion_date": "2023-10-01",
      "has_results": true,
      "last_update_posted_date": "2024-10-31",
      "last_synced_at": "2026-07-22T14:14:15.745Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • Baltimore, Maryland • Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03973918"
    },
    {
      "nct_id": "NCT01009866",
      "title": "Study of Immunotoxin, MR1-1",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Supratentorial Malignant Brain Tumor"
      ],
      "interventions": [
        {
          "name": "MR1-1",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Darell D. Bigner, MD, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2006-11",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2015-03-20",
      "last_synced_at": "2026-07-22T14:14:15.745Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01009866"
    },
    {
      "nct_id": "NCT02323880",
      "title": "Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Glioma",
        "Recurrent Brain Neoplasm",
        "Recurrent Childhood Central Nervous System Neoplasm",
        "Recurrent Childhood Glioblastoma",
        "Recurrent Lymphoma",
        "Recurrent Malignant Solid Neoplasm",
        "Refractory Lymphoma",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Primary Central Nervous System Neoplasm",
        "WHO Grade 3 Glioma"
      ],
      "interventions": [
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Selinexor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "12 Months to 21 Years"
      },
      "enrollment_count": 59,
      "start_date": "2015-10-30",
      "completion_date": "2024-12-31",
      "has_results": true,
      "last_update_posted_date": "2025-01-14",
      "last_synced_at": "2026-07-22T14:14:15.745Z",
      "location_count": 23,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02323880"
    },
    {
      "nct_id": "NCT00108056",
      "title": "Enzastaurin to Treat Recurrent Brain Tumor",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioma"
      ],
      "interventions": [
        {
          "name": "Enzastaurin (LY317615) monohydronchloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2005-04-07",
      "completion_date": "2014-04-01",
      "has_results": false,
      "last_update_posted_date": "2019-12-05",
      "last_synced_at": "2026-07-22T14:14:15.745Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00108056"
    },
    {
      "nct_id": "NCT01257594",
      "title": "EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain Cancer"
      ],
      "interventions": [
        {
          "name": "erlotinib",
          "type": "DRUG"
        },
        {
          "name": "Cytoreductive Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Andrew B Lassman, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2011-01-07",
      "completion_date": "2018-12-31",
      "has_results": false,
      "last_update_posted_date": "2023-05-25",
      "last_synced_at": "2026-07-22T14:14:15.745Z",
      "location_count": 4,
      "location_summary": "Basking Ridge, New Jersey • Commack, New York • New York, New York",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01257594"
    },
    {
      "nct_id": "NCT04485559",
      "title": "Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent World Health Organization (WHO) Grade II Glioma",
        "Low-grade Glioma",
        "High Grade Glioma"
      ],
      "interventions": [
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Trametinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "1 Year to 25 Years"
      },
      "enrollment_count": 50,
      "start_date": "2020-12-09",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-17",
      "last_synced_at": "2026-07-22T14:14:15.745Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 14 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04485559"
    },
    {
      "nct_id": "NCT05917145",
      "title": "ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Treatment of Recurrent High-Grade Glioma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "WSD0628",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 94,
      "start_date": "2024-01-17",
      "completion_date": "2029-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-21",
      "last_synced_at": "2026-07-22T14:14:15.745Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05917145"
    },
    {
      "nct_id": "NCT02168270",
      "title": "Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anaplastic Astrocytoma",
        "Anaplastic Oligodendroglioma",
        "Anaplastic Oligoastrocytoma",
        "Glioblastoma",
        "Gliosarcoma"
      ],
      "interventions": [
        {
          "name": "ascorbic acid",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "temozolomide",
          "type": "DRUG"
        },
        {
          "name": "quality-of-life assessment",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2014-06-16",
      "completion_date": "2015-08-20",
      "has_results": true,
      "last_update_posted_date": "2023-11-24",
      "last_synced_at": "2026-07-22T14:14:15.745Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02168270"
    },
    {
      "nct_id": "NCT00671970",
      "title": "Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma",
        "Gliosarcoma"
      ],
      "interventions": [
        {
          "name": "Bevacizumab and Erlotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 57,
      "start_date": "2007-02",
      "completion_date": "2010-04",
      "has_results": true,
      "last_update_posted_date": "2013-05-13",
      "last_synced_at": "2026-07-22T14:14:15.745Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00671970"
    }
  ]
}